Media Articles Related to Inversine (Mecamylamine)
Late-onset hypertension may lower dementia risk, study finds
Source: Hypertension News From Medical News Today [2017.01.17]
For the first time, a study investigates the link between high blood pressure later in life and the risk of dementia and cognitive decline.
New guidelines raise upper hypertension limit for 'otherwise healthy' over-60s
Source: Hypertension News From Medical News Today [2017.01.17]
New guidelines say treat otherwise healthy patients aged 60 and older when persistent systolic blood pressure is at or above 150 mm Hg, not 140 mm Hg.
Hypertension and prehypertension underdiagnosed and undertreated in US children
Source: Hypertension News From Medical News Today [2016.11.24]
Hypertension and prehypertension in children often go undiagnosed, according to a new study published in Pediatrics.
Immune cells identified as the culprit linking hypertension and dementia
Source: Hypertension News From Medical News Today [2016.11.16]
Hypertension is a leading risk factor for dementia and other disorders associated with cognitive decline.
Offspring may have higher risk for developing hypertension if their parents had hypertension before age 55
Source: Hypertension News From Medical News Today [2016.11.14]
If your parents were diagnosed with high blood pressure before age 55, you may be at higher risk for developing high blood pressure than if they developed hypertension at a later age, according to...
Published Studies Related to Inversine (Mecamylamine)
Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: a preliminary study. [2009.12]
Individuals with schizophrenia have higher plasma nicotine levels in comparison to non-psychiatric smokers, even when differences in smoking are equated. This difference may be related to how intensely cigarettes are smoked but this has not been well studied... Further work is needed to assess whether nicotine levels are directly mediated by how intensely the cigarettes are smoked, and to confirm whether this effect is more pronounced in smokers with schizophrenia.
Effects of acute ultra-low dose mecamylamine on cognition in adult attention-deficit/hyperactivity disorder (ADHD). [2009.06]
OBJECTIVE: Nicotinic cholinergic stimulation has known beneficial effects in attention-deficit/hyperactivity disorder (ADHD). Mecamylamine is a non-competitive nicotinic antagonist which is reported in several animal studies to have paradoxical positive effects on cognition at ultra-low doses. Comparable studies in humans have not been conducted. The aim of this study was to determine the effects of acute ultra-low doses of mecamylamine on cognition in adult ADHD... CONCLUSION: This is the first study to find measurable effects of ultra-low doses of mecamylamine in humans. Mecamylamine did not improve core ADHD cognitive symptoms, but significantly improved recognition memory. These effects may represent mixed receptor activity (activation and blockade) at the doses tested. The finding of beneficial effects on memory processes has important clinical implications and further exploration of this effect is warranted.
A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers. [2007.05]
AIMS: To determine the efficacy and safety of nicotine transdermal therapy co-administered with the nicotine antagonist, mecamylamine, compared to a nicotine transdermal patch alone (21 mg nicotine + 6 mg mecamylamine, 21 mg nicotine + 3 mg mecamylamine, and 21 mg nicotine + 0 mg mecamylamine)... CONCLUSION: If adding mecamylamine to nicotine replacement therapy (NRT) improves the chances of success at stopping smoking, the results of this study suggest that the effect is very small.
A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers. [2007.03.01]
Aims To determine the efficacy and safety of nicotine transdermal therapy co-administered with the nicotine antagonist, mecamylamine, compared to a nicotine transdermal patch alone (21 mg nicotine + 6 mg mecamylamine, 21 mg nicotine + 3 mg mecamylamine, and 21 mg nicotine + 0 mg mecamylamine)...
The influence of mecamylamine on trigeminal and olfactory chemoreception of nicotine. [2006.02]
Nicotine presented to the nasal cavity at low concentrations evokes 'odorous' sensations, and at higher concentrations 'burning' and 'stinging' sensations. A study in smokers and nonsmokers provided evidence of a relationship between the experience with the pharmacological action of S-(-)-nicotine and the perceived pleasantness/unpleasantness following nasal stimulation with S-(-)-nicotine...
Clinical Trials Related to Inversine (Mecamylamine)
Study of the Effects of Mecamylamine and Varenicline in Schizophrenia [Completed]
We are conducting this study to find out if blocking or partially stimulating the effects of
nicotine in the brain can affect memory and concentration. Nicotine is the addictive drug
found in tobacco products. Our subjects will be people with and without mental illness
(schizophrenia), smokers and non-smokers.
We will use a medication called mecamylamine (Inversine) to block the effects of nicotine on
the brains of our subjects. We will also use a medication called varenicline (Chantix) to
partially increase the effects of nicotine on the brains of our subjects. This study also
uses a placebo, a pill that does not have any active ingredients but looks exactly like the
mecamylamine and varenicline pills. We will compare the effects of giving mecamylamine or
placebo to people who have schizophrenia and people who do not have schizophrenia.
We know that people with schizophrenia smoke heavily and find it harder to stop smoking than
most other people do. Studies have shown that people with schizophrenia may smoke more
because nicotine helps their concentration and memory. We are interested in helping people
with schizophrenia smoke less. Mecamylamine blocks the parts of the brain that react to
nicotine and varenicline partially stimulates and partially blocks the parts of the brain
that react to nicotine. Both medications may decrease the effects that smoking has on the
Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders [Completed]
Nicotinic Modulation of the Default Network [Completed]
Many disorders where attentional problems are a hallmark, such as Alzheimer's disease and
schizophrenia, display abnormal regulation of the so-called default network of resting brain
function that maintains internally directed thought when the mind is free to wander. These
regions can be overactive or less readily deactivated with attention-demanding tasks, and
excess activity is thought to impair performance. There is indication that nicotine may
improve attention by aiding the deactivation of the default network, and this mechanism may
be of therapeutic benefit for the above disease states. The current project aims at
providing a proof of concept by demonstrating that nicotinic drugs modulate default network
function. The nicotinic agonist nicotine is hypothesized to improve attention by
facilitating the down-regulation of default network activity, and the nicotinic antagonist
mecamylamine is hypothesized to impair attention by impeding the down-regulation of default
network activity during attentional task performance.
Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients [Recruiting]
The purpose of the study will be to evaluate the efficacy of mecamylamine in reducing
alcohol consumption in smoking and non-smoking alcohol dependent patients.
We hypothesize that mecamylamine will result in a greater reduction of alcohol consumption
than placebo. We further hypothesize that mecamylamine will be effective in reducing both
alcohol consumption and smoking in a subset of alcoholics who also smoke.
Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence [Completed]
The objective of this study is to evaluate the efficacy of mecamylamine (MEC, 10 mg/day)
versus placebo in reducing depressive and alcohol symptoms in patients with depression and
co-morbid alcohol dependence. The researchers hypothesize that MEC will significantly
reduce depressive symptoms and decrease alcohol consumption compared to placebo in patients
with depression and alcohol dependence who are on a stable dose of a selective serotonin
reuptake inhibitor (SSRI).